BeOne Medicines
3 clinical trials · 3 recruiting · INDUSTRY
Trials by BeOne Medicines
RECRUITINGPhase 3NCT06846671
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small...
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine...
Sponsor: BeOne MedicinesEnrolling: 25020 locations
CLLChronic Lymphocytic Leukemia
RECRUITINGPhase 1NCT06427941
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants...
This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033...
Sponsor: BeOne MedicinesEnrolling: 14019 locations
Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2
RECRUITINGPhase 1 / Phase 2NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus...
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R)...
Sponsor: BeOne MedicinesEnrolling: 24620 locations
Relapsed/Refractory Multiple Myeloma